Role of antithrombin concentrate in treatment of hereditary antithrombin deficiency: An update

Thrombosis and Haemostasis

Volumn 101, Issue 5, 2009, Pages 806-812

  Rodgers, George M ^a  

^a UNIVERSITY OF UTAH HEALTH SCIENCES CENTER   (United States)

Author keywords

Antithrombin; Hereditary antithrombin deficiency; Thromboprophylaxis; Venous thromboembolism

Indexed keywords

ANTITHROMBIN; ANTITHROMBIN III; ANTITHROMBIN III CONCENTRATE; FRESH FROZEN PLASMA; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; RECOMBINANT ANTITHROMBIN III; THROMBATE; TISSUE FACTOR PATHWAY INHIBITOR; UNCLASSIFIED DRUG; VITAMIN K GROUP;

ABDOMINAL CRAMP; ANTICOAGULATION; ANTIINFLAMMATORY ACTIVITY; ANTITHROMBIN DEFICIENCY; AUTOSOMAL DOMINANT INHERITANCE; BLOOD TRANSFUSION; CHEST TIGHTNESS; COMPARATIVE STUDY; CONTROLLED STUDY; COST MINIMIZATION ANALYSIS; DELIVERY; DISSEMINATED INTRAVASCULAR CLOTTING; DIZZINESS; DRUG COST; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FETOTOXICITY; FEVER; FOOD AND DRUG ADMINISTRATION; GENE MUTATION; GENETIC DISORDER; HERITABILITY; HETEROZYGOSITY; HOMOZYGOSITY; HOSPITAL COST; HUMAN; LABOR; MONOTHERAPY; MUTATIONAL ANALYSIS; POINT MUTATION; PRACTICE GUIDELINE; PREGNANCY; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SHORT COURSE THERAPY; SUBSTITUTION THERAPY; SURGICAL INJURY; THROMBOPHILIA; THROMBOSIS PREVENTION; TREATMENT INDICATION; VENOUS THROMBOEMBOLISM;

ANTICOAGULANTS; ANTITHROMBIN III; ANTITHROMBIN III DEFICIENCY; BLOOD COAGULATION; GENETIC PREDISPOSITION TO DISEASE; HEMORRHAGE; HEPARIN; HUMANS; PEDIGREE; PRACTICE GUIDELINES AS TOPIC; RISK ASSESSMENT; RISK FACTORS; TREATMENT OUTCOME; VENOUS THROMBOEMBOLISM;

EID: 66149176918     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH08-10-0672     Document Type: Review

References (69)

1. Maclean PS, Tait RC. Hereditary and acquired antithrombin deficiency: epidemiology, pathogenesis and treatment options. Drugs 2007; 67: 1429-1440. (Pubitemid 47026392)
2. Bauer KA. Selective inhibition of coagulation factors: advances in antithrombotic therapy. Semin Thromb Hemost 2002; 28 (Suppl 2): 15-24. (Pubitemid 34634350)
3. Bucur SZ, Levy JH, Despotis GJ, et al. Uses of antithrombin III concentrate in congenital and acquired deficiency states. Transfusion 1998; 38: 481-498. (Pubitemid 28287507)
4. Roemisch J, Gray E, Hoffmann JN, et al. Antithrombin: a new look at the actions of a serine protease inhibitor. Blood Coagul Fibrinolysis 2002; 13: 657-670. (Pubitemid 36026822)
5. Römisch J, Dönges R, Stauss H, et al. Quantification of antithrombin isoform proportions in plasma samples of healthy subjects, sepsis patients, and in antithrombin concentrates. Pathophysiol Haemost Thromb 2002; 32: 143-150. (Pubitemid 37490506)
6. Tanaka KA, Levy JH. Regulation of thrombin activity - pharmacologic and structural aspects. Hematol Oncol Clin North Am 2007; 21: 33-50. (Pubitemid 46156984)
7. Blajchman MA. An overview of the mechanism of action of antithrombin and its inherited deficiency states. Blood Coagul Fibrinolysis 1994; 5 (Suppl 1): S5-11; discussion S59-64.
8. Muñoz EM, Linhardt RJ. Heparin-binding domains in vascular biology. Arterioscler Thromb Vasc Biol 2004; 24: 1549-1557. (Pubitemid 39180876)
9. Opal SM. Interactions between coagulation and inflammation. Scand J Infect Dis 2003; 35: 545-554. (Pubitemid 37336871)
10. Senden NH, Jeunhomme TM, Heemskerk JW, et al. Factor Xa induces cytokine production and expression of adhesion molecules by human umbilical vein endothelial cells. J Immunol 1998; 161: 4318-4324. (Pubitemid 28469016)
11. Schwartz RS, Bauer KA, Rosenberg RD, et al. The Antithrombin III Study Group. Clinical experience with antithrombin III concentrate in treatment of congenital and acquired deficiency of antithrombin. Am J Med 1989; 87(Suppl 3B): 53S-60S.
12. Bauer KA, Rosenberg RD. The pathophysiology of the prethrombotic state in humans: insights gained from studies using markers of hemostatic system activation. Blood 1987; 70: 343-350. (Pubitemid 17142912)
13. Hirsh J, Piovellá F, Pini M. Congenital antithrombin III deficiency. Incidence and clinical features. Am J Med 1989; 87 (Suppl 3B): 34S-38S. (Pubitemid 19249549)
14. Franchini M, Veneri D, Salvagno GL, et al. Inherited thrombophilia. Crit Rev Clin Lab Sci 2006; 43: 249-290.
15. Wells PS, Blajchman MA, Henderson P, et al. Prevalence of antithrombin deficiency in healthy blood donors: a cross-sectional study. Am J Hematol 1994; 45: 321-324. (Pubitemid 24109908)
16. Buller HR, ten Cate JW. Acquired antithrombin III deficiency: laboratory diagnosis, incidence, clinical implications, and treatment with antithrombin III concentrate. Am J Med 1989; 87 (3B): 44S-48S.
17. Ranucci M, Frigiola A, Menicanti L, et al. Postoperative antithrombin levels and outcome in cardiac operations. Crit Care Med 2005; 33: 355-360. (Pubitemid 40216549)
18. Andrew M, Vegh P, Johnston M, et al. Maturation of the hemostatic system during childhood. Blood 1992; 80: 1998-2005.
19. Flanders MM, Phansalkar AR, Crist RA, et al. Pediatric reference intervals for uncommon bleeding and thrombotic disorders. J Pediatr 2006; 149: 275-277. (Pubitemid 44144496)
20. Haemostasis and Thrombosis Task Force of the British Committee for Standards in Haematology. Investigation and management of heritable thrombophilia. Br J Haematol 2001; 114: 512-528.
21. Kottke-Marchant K, Duncan A. Antithrombin deficiency: issues in laboratory diagnosis. Arch Pathol Lab Med 2002; 126: 1326-1336.
22. Lane DA, Kunz G, Olds RJ, et al. Molecular genetics of antithrombin deficiency. Blood Rev 1996; 10: 59-74. (Pubitemid 26234214)
23. Seligsohn U, Lubetsky A. Genetic susceptibility to venous thrombosis. N Engl J Med 2001; 344: 1222-1231. (Pubitemid 32319498)
24. Tait RC, Walker ID, Perry DJ, et al. Prevalence of antithrombin deficiency in the healthy population. Br J Haematol 1994; 87: 106-112. (Pubitemid 24207007)
25. Martinelli I, Mannucci PM, De Stefano V, et al. Different risks of thrombosis in four coagulation defects associated with inherited thrombophilia: a study of 150 families. Blood 1998; 92: 2353-2358. (Pubitemid 28452977)
26. Perry SL, Ortel TL. Clinical and laboratory evaluation of thrombophilia. Clin Chest Med 2003; 24: 153-170. (Pubitemid 36363145)
27. van Boven HH, Reitsma PH, Rosendaal FR, et al. Factor V Leiden (FV R506Q) in families with inherited antithrombin deficiency. Thromb Haemost 1996; 75: 417-421. (Pubitemid 26099705)
28. Thaler E, Lechner K. Antithrombin III deficiency and thromboembolism. Clin Haematol 1981; 10: 369-390.
29. Rossi E, Sz T, Ciminello A, et al. The risk of symptomatic pulmonary embolism due to proximal deep venous thrombosis differs in patients with different types of inherited thrombophila. Thromb Haemost. 2008; 99: 1030-1034.
30. Bates SM, Greer IA, Pabinger I, et al. Venous thromboembolism, thrombophilia, antithrombotic therapy, and pregnancy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133 (6 Suppl): 844S-886S.
31. Bharadwaj J, Jayaraman C, Shrivastava R. Heparin resistance. Lab Hematol 2003; 9: 125-131. (Pubitemid 37220791)
32. Avidan MS, Levy JH, Scholz J, et al. A phase III, double-blind, placebo-controlled, multicenter study on the efficacy of recombinant human antithrombin in heparin- resistant patients scheduled to undergo cardiac surgery necessitating cardiopulmonary bypass. Anesthesiology 2005; 102: 276-284. (Pubitemid 40189074)
33. Avidan MS, Levy JH, van Aken H, et al. Recombinant human antithrombin III restores heparin responsiveness and decreases activation of coagulation in heparin- resistant patients during cardiopulmonary bypass. J Thorac Cardiovasc Surg 2005; 130: 107-113. (Pubitemid 40941676)
34. Edmunds LH Jr, Colman RW. Thrombin during cardiopulmonary bypass. Ann Thorac Surg 2006; 82: 2315-2322.
35. Ranucci M, Isgró G, Cazzaniga A, et al. Different patterns of heparin resistance: therapeutic implications. Perfusion 2002; 17: 199-204. (Pubitemid 34467126)
36. Staples MH, Dunton RF, Karlson KJ, et al. Heparin resistance after preoperative heparin therapy or intraaortic balloon pumping. Ann Thorac Surg 1994; 57: 1211-1216. (Pubitemid 24204506)
37. Williams MR, D'Ambra AB, Beck JR, et al. A randomized trial of antithrombin concentrate for treatment of heparin resistance. Ann Thorac Surg 2000; 70: 873-877.
38. Hirsh J, Raschke R. Heparin and low-molecular-weight heparin. Chest 2004; 126: 188S-203S.
39. MacLennan S, Barbara JA. Risks and side effects of therapy with plasma and plasma fractions. Best Pract Res Clin Haematol 2006; 19: 169-189. (Pubitemid 43118870)
40. Stramer SL, Fang CT, Foster GA, et al. West Nile virus among blood donors in the United States, 2003 and 2004. N Engl J Med 2005; 353: 451-459.
41. Thrombate III® [package insert]. Research Triangle Park, NC: Talecris Biotherapeutics, Inc; 2005.
42. Hoffman DL. Purification and large-scale preparation of antithrombin III. Am J Med 1989; 87 (3B): 23S-26S.
43. Morrica A, Nardini C, Falbo A, et al. Manufacturing process of anti-thrombin III concentrate: viral safety validation studies and effect of column re-use on viral clearance. Biologicals 2003; 31: 165-173. (Pubitemid 36993712)
44. Menache D, O'Malley JP, Schorr JB, et al. Cooperative Study Group. Evaluation of the safety, recovery, half-life, and clinical efficacy of antithrombin III (human) in patients with hereditary antithrombin III deficiency. Blood 1990; 75: 33-39.
45. Preiss DU, Abdullah D, Eberspacher B, et al. Safety of virus inactivated antithrombin III concentrate antithrombin III immuno (AT III). Thromb Res 1992; 65: 677-686.
46. Edmunds T, Van Patten SM, Pollock J, et al. Transgenically produced human antithrombin: structural and functional comparison to human plasma-derived antithrombin. Blood 1998; 91: 4561-4571. (Pubitemid 28270304)
47. Konkle BA, Bauer KA, Weinstein R, et al. Use of recombinant human antithrombin in patients with congenital antithrombin deficiency undergoing surgical procedures. Transfusion 2003; 43: 390-394. (Pubitemid 36351132)
48. Tiede A, Tait RC, Shaffer DW, et al. Antithrombin alfa in hereditary antithrombin deficient patients: A phase 3 study of prophylactic intravenous administration in high risk situations. Thromb Haemost 2008; 99: 616-622.
49. Lockwood CJ. Inherited thrombophilias in pregnant patients: detection and treatment paradigm. Obstet Gynecol 2002; 99: 333-341. (Pubitemid 34114007)
50. Rey E, Kahn SR, David M, et al. Thrombophilic disorders and fetal loss: a meta-analysis. Lancet 2003; 361: 901-908. (Pubitemid 36335814)
51. Robertson L, Wu O, Langhorne P, et al. Thrombophilia in pregnancy: a systematic review. Br J Haematol 2005; 132: 171-196. (Pubitemid 43381552)
52. Hellgren M, Tengborn L, Abildgaard U. Pregnancy in women with congenital antithrombin III deficiency: experience of treatment with heparin and antithrombin. Gynecol Obstet Invest 1982; 14: 127-141.
53. Folkeringa N, Brouwer JL, Korteweg FJ, et al. Reduction of high fetal loss rate by anticoagulant treatment during pregnancy in antithrombin, protein C or protein S deficient women. Br J Haematol 2007; 136: 656-661. (Pubitemid 46148204)
54. Yamada T, Yamada H, Morikawa M, et al. Management of pregnancy with congenital antithrombin III deficiency: two case reports and a review of the literature. J Obstet Gynaecol Res 2001; 27: 189-197. (Pubitemid 33034793)
55. British Committee for Standards in Haematology. Guidelines on the investigation and management of thrombophilia. The British Committee for Standards in Haematology. J Clin Pathol 1990; 43: 703-709.
56. Brenner B, Tavori S, Tatarsky I. Prophylaxis of thromboembolism during pregnancy in hereditary AT-III deficiency. Am J Hematol 1992; 39: 71-72.
57. Inomoto T, Takamoto M, Tamura R, et al. Effective prophylaxis of thrombosis by antithrombin III concentrate in a pregnant woman with congenital antithrombin III deficiency: relations between plasma antithrombin III activity and the plasma levels of hemostatic molecular markers. Haemostasis 1991; 21: 147-154.
58. Megha A, Finzi G, Poli T, et al. Pregnancy, antithrombin III deficiency and venous thrombosis: report of another case. Acta Haematol 1990; 83: 111. (Pubitemid 20043283)
59. Shiozaki A, Arai T, Izumi R, et al. Congenital antithrombin III deficient neonate treated with antithrombin III concentrates. Thromb Res 1993; 70: 211-216. (Pubitemid 23151327)
60. Tengborn L, Bengtsson T. Antithrombin III concentrate. Thromboprophylaxis during pregnancy in a patient with congenital antithrombin III deficiency. Acta Obstet Gynecol Scand 1986; 65: 375-376.
61. De Stefano V, Leone G, De Carolis S, et al. Management of pregnancy in women with antithrombin III congenital defect: report of four cases. Thromb Haemost 1988; 59: 193-196. (Pubitemid 18103871)
62. Michiels JJ, Stibbe J, Vellenga E, et al. Prophylaxis of thrombosis in antithrombin III-deficient women during pregnancy and delivery. Eur J Obstet Gynecol Reprod Biol 1984; 18: 149-153. (Pubitemid 15202415)
63. Samson D, Stirling Y, Woolf L, et al. Management of planned pregnancy in a patient with congenital antithrombin III deficiency. Br J Haematol 1984; 56: 243-249. (Pubitemid 14175627)
64. Blanco AN, Meschengieser S, Penalva LB, et al. Prophylaxis during surgery in antithrombin III deficiency with low dose of concentrates. Thromb Res 1989; 56: 497-499. (Pubitemid 20003604)
65. Jackson MR, Olsen SB, Gomez ER, et al. Use of antithrombin III concentrates to correct antithrombin III deficiency during vascular surgery. J Vasc Surg 1995; 22: 804-807. (Pubitemid 26013939)
66. Mannucci PM, Boyer C, Wolf M, et al. Treatment of congenital antithrombin III deficiency with concentrates. Br J Haematol 1982; 50: 531-535. (Pubitemid 12184018)
67. Van Norman GA, Gernsheimer T, Chandler WL, et al. Indicators of fibrinolysis during cardiopulmonary bypass after exogenous antithrombin-III administration for acquired antithrombin III deficiency. J Cardiothorac Vasc Anesth 1997; 11: 760-763. (Pubitemid 27408675)
68. Red Book. 2006 ed. Montvale, NJ: Thomson PDR; 2006: 678.
69. Brown ME, Gallagher JM, Armitage JM. The use of antithrombin III concentrate for treatment of heparin resistance during cardiopulmonary bypass. J Extra-Corporeal Tech 2000; 32: 75-78. (Pubitemid 30432595)